Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.

Eli Lilly (NYSE: LLY) has seen revenue soar in recent quarters thanks to one portfolio in particular: its weight loss drugs. The company makes tirzepatide, commercialized as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but each of these drugs has been prescribed for patients aiming to shed pounds. And they both have been in high demand.These injectable drugs (as well as a weight loss candidate in pill form that soon may join this commercial portfolio) represent a huge growth engine for the pharmaceutical company. Just this week, though, Lilly signed a deal with President Donald Trump to lower the prices of these blockbusters. What does this mean for the company and for investors? Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool